Avacta said is continuing to work with the UK government’s CONDOR programme to obtain regulatory approval in the UK to use the test for diagnostic purposes too.
The bead-assisted mass spectrometry (‘BAMS’) assay uses Affirmer reagents specific to the SARS-CoV-2 virus to capture its spike protein from a sample for rapid detection by mass spectrometry.
Up to 1,000 samples a day could be analysed by a single technician using BAMS.
Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.